CD20 is not a poor prognostic factor for childhood B-lineage acute lymphoblastic leukemia with high white blood cell count.
- Author:
Lu-Yang ZHANG
1
;
Xiao-Juan CHEN
;
Shu-Chun WANG
;
Ye GUO
;
Wen-Yu YANG
;
Yu-Mei CHEN
;
Li ZHANG
;
Yao ZOU
;
Xiao-Fan ZHU
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. xfzhu@ihcams.ac.cn.
- Publication Type:Journal Article
- MeSH:
Antigens, CD20;
Antineoplastic Combined Chemotherapy Protocols;
Child;
Disease-Free Survival;
Humans;
Leukocyte Count;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;
diagnosis;
Prognosis;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2020;22(7):728-733
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the significance of CD20 combined with white blood cell (WBC) count at diagnosis in the prognosis assessment in children with B-lineage acute lymphoblastic leukemia (ALL).
METHODS:A retrospective analysis was performed on the medical data of 821 B-ALL children who were treated with CCLG-ALL2008 regimen from April 2008 to April 2015. Their survival status was followed up.
RESULTS:Among the 821 children, 547 (66.6%) were negative, while 274 (33.4%) were positive for CD20 expression. Among 694 children with WBC<50×10/L (lower WBC count), the 5-year EFS rates were 65.9%±3.2% and 77.3%±2.0% for CD20 positive and negative patients respectively (P=0.001); the 5-year OS rates were 78.3%±2.9% and 87.5%±1.6% for CD20 positive and negative patients respectively (P=0.005); CD20 positive expression was an independent risk factor for EFS (HR=1.634, P=0.001) and OS (HR=1.761, P=0.005). Among 127 children with WBC>50×10/L (higher WBC count), the 5-year EFS rates was 64.3%±7.7% and 53.7%±5.5% for CD20 positive and negative patients respectively (P=0.135); the 5-year OS rate was 81.4%±6.4% and 58.6%±5.6% for CD20 positive and negative patients respectively (P=0.022); CD20 positive expression was an independent protective factor for OS (HR=0.367, P=0.016).
CONCLUSIONS:In children with B-ALL who are treated with CCLG-ALL2008 regimen, those with CD20 positive expression in lower WBC count at diagnosis have a poor prognosis; however, those with CD20 positive expression in higher WBC count at diagnosis have a better long-time survival.
